Ipasa helps in Covid-19 fight
The Innovative Pharmaceutical Association South Africa (Ipsasa) has confirmed its commitment to continue supplying medicines to people living with chronic diseases during the Covid-19 lockdown period.
The association represents 26 research-based pharmaceutical companies.
Ipasa says the outbreak of the virus has shown that the most at-risk population are people older than 65, with underlying conditions such as cardiovascular disease, chronic lung disease, immunosuppression, diabetes, and liver and kidney diseases.
The association and its members say that, while health professionals and researchers worldwide work tirelessly to develop a vaccine for Covid-19, they are committed to ensuring that those with underlying conditions receive sufficient supply of much-needed medications.
Ipasa and its members remain sensitive to factors including safeguarding access to critical medicines, ensuring equitable access to critical medicines, contributing assets and expertise to help lessen the Covid-19 impact and contributing to the collection of data to support decision-making.
The healthcare sector is collaborating with various stakeholders to find solutions and flatten the curve of new infections.
Further, it has become more apparent that it is everyone’s responsibility to practice the highest standards of hygiene and practice physical distancing while the industry, academia, regulators, governments and the World Health Organization harness the power of science to develop a safe and effective vaccine for Covid-19.
Ipasa is joining hands with medical professionals and industry stakeholders to assist in any way possible. Medical doctors from member companies are volunteering their time at various hospitals and providing medical advice on the recently launched national medical support hotline.
Comments
The
content
you are trying to access is only available to subscribers.
If you are already a subscriber, you can Login Here.
If you are not a subscriber, you can subscribe now, by selecting one of the below options.
For more information or assistance, please contact us at subscriptions@creamermedia.co.za.
Option 1 (equivalent of R125 a month):
Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format
Option 2 (equivalent of R375 a month):
All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors
including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.
Already a subscriber?
Forgotten your password?
Receive weekly copy of Creamer Media's Engineering News & Mining Weekly magazine (print copy for those in South Africa and e-magazine for those outside of South Africa)
➕
Recieve daily email newsletters
➕
Access to full search results
➕
Access archive of magazine back copies
➕
Access to Projects in Progress
➕
Access to ONE Research Report of your choice in PDF format
RESEARCH CHANNEL AFRICA
R4500 (equivalent of R375 a month)
SUBSCRIBEAll benefits from Option 1
➕
Access to Creamer Media's Research Channel Africa for ALL Research Reports on various industrial and mining sectors, in PDF format, including on:
Electricity
➕
Water
➕
Energy Transition
➕
Hydrogen
➕
Roads, Rail and Ports
➕
Coal
➕
Gold
➕
Platinum
➕
Battery Metals
➕
etc.
Receive all benefits from Option 1 or Option 2 delivered to numerous people at your company
➕
Multiple User names and Passwords for simultaneous log-ins
➕
Intranet integration access to all in your organisation